Authors

Latest:

Dr Goldberg on the Investigation of VIC-1911 With/Without Sotorasib in KRAS G12C-Mutant NSCLC

Sarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.

Sarah B. Goldberg, MD, MPH, Yale Cancer Center

Sarah Crafton, MD

Latest:

Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Sarah E. Hoffe, MD

Latest:

Optimizing Advanced Technologies to Improve Outcomes in Esophageal Cancer

Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.

Sarah E. Taylor, MD

Latest:

Dr. Taylor on Molecular Testing Recommendations in Ovarian Cancer

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Sarah Ferguson, MD

Latest:

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.

Sarah Ferguson, MD, FRCSC

Latest:

Dr. Ferguson on Minimally Invasive Vs Open Surgery for Radical Hysterectomy in Cervical Cancer

Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.

Sarah Holstein, MD, PhD

Latest:

Dr. Holstein on BiTEs in Multiple Myeloma

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

Sarah K. Tasian, MD

Sarah K. Tasian, MD, is chief of the Hematologic Malignancies Program and the Joshua Kahan Endowed Chair in Pediatric Leukemia at the Children’s Hospital of Philadelphia.

Latest:

Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Sarah Karlovitch

Latest:

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

Sarah L. Sammons, MD

Latest:

Treatment Advances in HR+/HER2- MBC

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Sarah M. C. Sittenfeld, MD

Latest:

Neoadjuvant Radiosurgery Shows Efficacy for Large Brain Metastases

Neoadjuvant stereotactic radiosurgery has gained interest. This approach allows for easier target delineation; a smaller margin of normal brain parenchymal receiving the radiosurgery dose, which may decrease toxicity; and the potential to reduce the risk of leptomeningeal disease by sterilizing the tumor margin preoperatively.

Sarah M. Larson, MD

Latest:

Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple Myeloma

Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.

Sarah Popek, MD

Latest:

Colorectal Cancer: A Review

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Sarah Rutherford, MD

Latest:

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Sarah Wilcott-Sapp, MD

Latest:

Oncology Surgeons Need Better Training in Palliative Care

It is important for oncology surgeon trainees to learn to recognize when a palliative surgical procedure for an advanced malignancy might be appropriate, be familiar with the conduct of these operations, and understand the nuances of postoperative care and management of complications in this unique patient population.

Sarat Chandarlapaty, MD, PhD

Latest:

Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.

Sattva Neelapu, MD

Latest:

Dr Neelapu on Clinical Trial Data With CAR T-Cell Therapy in Lymphoma

Sattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.

Sattva S. Neelapu, MD

Latest:

Dr Neelapu on 5-Year Data for Axi-Cel in R/R Follicular Lymphoma and MZL

Sattva S. Neelapu, MD, discusses a 5-year follow-up data for axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Sattva S. Neelapu, MD, University of Texas MD Anderson Cancer Center